424results about "Drug screening" patented technology

The invention discloses a perfusion-free parallel double-cell intestine-liver chip system and application thereof in drug uptake evaluation, and belongs to the field of biomedical engineering and organ chips. The chip disclosed by the invention is simple in structure, free of an external pump and a complex pipeline, capable of realizing fluid circulation through swinging, convenient to operate, low in cost and small in pollution risk, and also capable of promoting cell differentiation and optimizing hepatocyte functions. The chip integrates a parallel intestinal cell and a liver cell which are communicated through a shared channel, can continuously simulate intestinal absorption and liver first-pass metabolism, and is closer to an in-vivo physiological state. The device adopts a detachable transparent modular design, can be repeatedly used, supports multi-group parallel operation, can improve experimental flux and result repeatability, and is suitable for in-vitro verification of drug absorption, permeability and metabolism evaluation.

The invention provides hindbrain organoids and methods of producing such organoids. Said hindbrain organoids may include healthy or healthy and diseased tissue. Also provided are methods of testing therapeutic agents using said hindbrain organoids. The invention also provides culture mediums used for producing (patterning) said hindbrain organoids and kits including the culture medias.

The present disclosure provides methods of making tissue-derived epithelial organoids. In particular, the present disclosure provides a tissue-derived epithelial organoid embedded in a hydrogel suspended in a culture medium. The present disclosure further provides methods of using such organoids.

The invention discloses construction of myocardial cells differentiated from propionemia stem cells based on a CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The model constructed by the invention has the metabolic phenotype of propionemia and can also be differentiated into myocardial cells. A reliable and effective experimental model is provided for research of propionemia disease related targets and screening of drugs for preventing / treating propionemia, and the method has a wide application prospect.

The invention relates to biomedical engineering, and discloses a biochip screening method of a therapeutic agent based on intestinal brain axis regulation and application thereof. The screening method comprises the following steps: performing intestinal wall cell culture or microglial cell culture by adopting a metasurface plasmon resonance biochip of which the surface is subjected to bionic treatment to obtain an intestinal wall cell adherent chip board or a microglial cell adherent chip board; the method comprises the following steps: adding a culture medium containing a chemotherapeutic drug or lipopolysaccharide into a cell-adherent chip board for culture I, then removing the culture medium, adding a therapeutic agent to be detected for culture II to obtain a culture solution, and detecting the cell repair effect of intestinal wall cells or microglial cells in the culture solution, and screening to obtain a therapeutic agent with a repairing effect on intestinal wall cells and / or microglial cells. The screening method can be used for efficiently and accurately screening the therapeutic agent with dual effects of intestinal regulation and neuroprotection from a plurality of therapeutic agents to be detected, and can be used for dynamically monitoring and exploring the interaction condition of the therapeutic agent and cells on line in an unmarked and real-time manner.

Systems and methods consistent with the present invention generally relate to microorganospheres (MOSs), and methods and apparatuses for forming and using MOSs. More particularly, in some embodiments, systems and methods consistent with the invention relate to the methods and apparatuses for forming and using MOSs generated from hepatocytes. MOSs that are generated from hepatocytes are suitable for testing liver toxicity and drug induced liver injury effects of various agents.

To provide ectodermal mesenchymal stem cells and methods for producing the same.SOLUTION: A method for producing ectodermal mesenchymal stem cells includes the step of selectively collecting, from peripheral blood of a subject administered with a peptide composed of an amino acid sequence of SEQ ID NO: 1, either (a) PDGFRα-positive and CD34-positive cells or (b) PDGFRβ-positive and CD34-positive cells.SELECTED DRAWING: None

To provide a method for generating oligocortical spheroids (OCS) from pluripotent stem cells (PSC).SOLUTION: A method comprises the steps for: a) generating a neurocortical spheroid (NCS) through neurocortical patterning of pluripotent stem cells; b) subjecting the neurocortical spheroid to timed exposure to defined oligodendrocyte lineage growth factors and / or hormones, to promote proliferation, survival and / or expansion of native oligodendrocyte progenitor cell (OPC) populations within the neurocortical spheroid, thereby generating the oligocortical spheroid, wherein the oligocortical spheroid contains oligodendrocyte progenitor cells capable of differentiating into myelinating oligodendrocytes (ODCs) that are capable of myelinating axons.SELECTED DRAWING: Figure 1-1

The invention discloses a human immortalized pure renal cyst cell line SRC-X1 and application thereof, and belongs to the field of microbial animal cell lines. The human immortalized pure renal cyst cell line is named as SRC-X1, the cell line is preserved in the China Center for Type Culture Collection on September 19, 2025, and the preservation number is CCTCC NO: C2025303. The human immortalized pure renal cyst cell line SRC-X1 is applied to preparation, screening or evaluation of renal cyst treatment drugs. The invention also discloses the application of the human immortalized pure renal cyst cell line SRC-X1 as a renal cyst cell model. The human immortalized pure renal cyst cell line SRC-X1 is applied to renal cyst basic or clinical research as an experimental material.

The invention discloses application of ceramide and a synthetic regulating agent thereof in regulating porcine epidemic diarrhea virus infection, and belongs to the technical field of biology. Experiments prove that the mRNA expression quantity and virus titer of PEDV (porcine epidemic diarrhea virus) in IPEC-J2 cells are remarkably improved by exogenously adding C24-ceramide or regulating and controlling the endogenous ceramide level through a ceramide enzyme inhibitor, and a ceramide synthesis inhibitor shows a remarkable antiviral effect. The invention proves that ceramide is a key factor for PEDV (porcine epidemic diarrhea virus) replication, and an inhibitor targeting a ceramide synthetic route can effectively inhibit PEDV infection, so that a theoretical basis and an experimental basis are provided for constructing a porcine epidemic diarrhea virus susceptibility model and developing a novel anti-PEDV drug.

The invention belongs to the cross technical field of veterinary medicine and biomedicine, and relates to a construction and evaluation method of a dog spontaneous breast cancer organoid model, which specifically comprises the following steps: (1) obtaining dog spontaneous breast cancer tissues through operation or biopsy, separating tumor tissues under sterile conditions, and carrying out fine enzymolysis digestion treatment to obtain dog spontaneous breast cancer tissues; obtaining a single-cell suspension; and (2) inoculating the single-cell suspension into a three-dimensional culture system, carrying out three-dimensional culture by adopting a culture medium containing EGF, FGF and B27 in combination with a growth factor, promoting the growth and amplification of the breast cancer organs, and carrying out timely passage according to the growth condition so as to maintain the activity of the model. The model constructed by the invention completely retains genetic heterogeneity and pathological microenvironment of primary tumors, does not need gene editing, is simple and convenient to operate and low in cost, is particularly suitable for individual drug sensitivity detection of pet dogs, and provides an efficient and high-simulation experimental platform for dog breast cancer mechanism research and clinical precise medication.

A culture medium and a culture method for human primary acute myeloid leukemia cells are provided. The culture medium for human primary acute myeloid leukemia cells includes glutamine additive, non-essential amino acids, human interleukin-6, human interleukin-7, human interleukin-3, recombinant human FLT3 ligand, recombinant human macrophage colony-stimulating factor, and human stem cell factor. By using the above culture medium and culture method, acute myeloid leukemia cells can be cultured with higher expansion efficiency and longer in-vitro culture time. Also provided are human primary acute myeloid leukemia cells cultured in vitro using the culture medium, and its use for evaluating and screening the therapeutic effect of drugs.

The purpose of the present invention is to provide skin care focusing on the sense of touch. It was found that sandalore and an analog thereof have an action of activating Merkel cells. Provided is a Merkel cell activator containing sandalore and an analog thereof. It was also found that an activated Merkel cell contains a large number of synaptic vesicles. Provided is a synaptic vesicle enhancer containing sandalore and an analog thereof. It was also found that the neurotransmitter release activity of Merkel cells can be assessed by measuring, under a fluorescence microscope, changes in fluorescent luminance value before and after depolarization stimulation to Merkel cells that have taken in a fluorescent tracer. Provided is a method for screening for a neurotransmitter release accelerator for Merkel cells.

The present invention addresses the problem of providing a device for simultaneously measuring an electrical signal and a contractile force using a highly mature cardiac muscle tissue having a 3D / oriented structure close to a cardiac muscle structure in a living body. As a solution, provided is a device for measuring the contractility of a cardiac muscle tissue, which is provided with a contractile part that includes a rod-like artificial cardiac muscle tissue that has a three-dimensional structure and in which cardiac muscle cells are oriented in the longitudinal direction, and which is used to measure the contractility of the contractile part.

The application belongs to the technical field of biotechnology, and particularly relates to a human metapneumovirus mouse-adapted strain and application thereof. Compared with wild strains, the strain can exhibit stronger susceptibility to animals, and can cause typical clinical symptoms and even death. For example, after the strain infects BALB / c mice, the disease symptoms are obvious, 83% of the mice have a severe decrease in body weight to below 75% after infection, and have reached the humane killing standard. Four days after the strain infects BALB / c mice, the mortality rate is above 50%. The strain can be used to construct a cell model or an animal model of human metapneumovirus infection or a disease caused by the human metapneumovirus, and is further used to screen drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus. In addition, the strain can also be used to prepare drugs for preventing and / or treating human metapneumovirus infection or a disease caused by the human metapneumovirus, and to prepare antibodies or antisera against the human metapneumovirus.

A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.

The application provides a pulmonary artery tissue-derived cell, an organoid and a construction method and application thereof. The pulmonary artery intimal stripping tissue organoid structure obtained by the preparation method is clear, has consistent cell types as the source tissue, is close to the original tissue, is convenient for researchers to operate, and thus has good practical application value.

A human sebaceous gland carcinoma cell line and use thereof are provided. The human sebaceous gland carcinoma cell line SHNPH-SeC was deposited in the China Center for Type Culture Collection (CCTCC) on Aug. 31, 2023, with an accession number CCTCC NO: C2023113. The human sebaceous gland carcinoma cell line SHNPH-SeC carries a TP53 mutation, and has been identified as a novel single cell line by short tandem repeat (STR) genotyping. This human sebaceous gland carcinoma cell line exhibits strong adherence and stable cellular characteristics, can be stably passaged for multiple generations, and possesses rapid proliferation and migration capabilities, which are in line with the characteristics of malignant tumor cells.

The invention belongs to the technical field of bioengineering, and relates to heparan sulfate defect type matrigel as well as a preparation method and application thereof. The preparation method comprises the following steps: providing natural matrigel; providing immobilized heparinase, wherein the immobilized heparinase can specifically catalyze and degrade heparan sulfate in the natural matrigel; carrying out contact reaction on the natural matrigel and the immobilized heparinase; and after the reaction is finished, separating the immobilized heparinase. According to the preparation method, the characteristics that the immobilized enzyme is convenient to separate and recycle are utilized, the problems that in a traditional solution enzyme method, enzyme residues exist, the reaction is difficult to accurately control, and subsequent purification steps are complex are solved, and a standardized heparan sulfate defective matrigel product which is controllable in component, free of residual enzyme and high in stability is provided. The method has wide application value in the fields of tumor mechanism research, anti-tumor drug screening, tissue engineering and the like.

The invention provides a construction method of a non-small cell lung cancer histone H1.3 arginine methylation point mutation cell model. The construction method comprises the following steps: designing mutation primers H1.3 R80A-F and H1.3 R80A-R; the method comprises the following steps: by taking a pCDH-HA-H1.3-Flag plasmid as a template, carrying out PCR (Polymerase Chain Reaction) amplification by adopting a mutation primer, digesting a product by DMT enzyme, and converting a competent cell to obtain a mutant plasmid; and co-transfecting the mutant plasmid and a helper plasmid to a packaging cell, collecting a virus solution, filtering, infecting an A549 cell, adding Polybrene to assist infection, culturing, and screening a stably transfected cell strain by using puromycin to obtain the recombinant plasmid. The invention also provides application of the mutant cell model obtained by the construction method. According to the invention, the blank of histone H1.3 methylation research is filled, the 80th arginine is clear as a core modification site, and the established model provides a new tool for lung cancer mechanism research and drug research and development.

The invention discloses an organoid culture medium, a kit and a method for culturing an organoid, and relates to the technical field of organoid culture. The organoid culture medium provided by the invention can improve the proliferation activity of the organoid, a relatively complete organoid form can be obtained through culture, and the cost of the culture medium is reduced. The tumor cell organoid obtained by adopting the organoid culture medium provided by the invention has a more complete tumor cell surface marker, and the cell damage is smaller.

This method for producing a brain organoid including aggregated tau protein comprises: a step (a) for culturing pluripotent stem cells in the presence of SMAD inhibitor to form embryoid bodies; a step (b) for embedding the embryoid bodies in an extracellular matrix and three-dimensionally culturing the embryoid bodies in the presence of SMAD inhibitor and GSK3β inhibitor to form an organoid that includes neural precursor cells; a step (c) for removing the organoid from the extracellular matrix and suspension-culturing the organoid in the presence of LIF to form a brain organoid; a step (d) for forcing the brain organoid to express a modified MAPT gene; and a step (e) for further suspension-culturing the brain organoid after step (d) to obtain a brain organoid having an aggregated tau protein.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.

The invention relates to the technical field of biology, and discloses a method for constructing a drosophila embryo permeabilization model, which comprises the following steps: collecting and cleaning drosophila embryos: collecting and washing the drosophila embryos; rinsing the drosophila melanogaster embryos, namely rinsing the drosophila melanogaster embryos by using a bleaching agent solution to remove chorion layers of the drosophila melanogaster embryos, and washing the embryos after rinsing; and performing permeation treatment on the drosophila melanogaster embryo: performing permeation treatment on the drosophila melanogaster embryo without the chorion layer in an embryo permeation solution EPS, and then cleaning in BPS to obtain the drosophila melanogaster embryo permeation model. According to the construction method of the drosophila melanogaster embryo permeabilization model, operation is easy, convenient and rapid, it can be guaranteed that embryo permeability is good, embryo vitality is maintained at the same time, the influence of small molecule drugs on the embryo development process is conveniently studied, and the method is suitable for popularization and application. And favorable conditions are provided for researching cell and molecular mechanisms of embryonic development, toxicological evaluation of small molecular substance screening and screening of related drugs in an embryo model.

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

The invention provides a nucleic acid construct which comprises an immune response regulatory sequence and a coding sequence of a reporter gene driven by a promoter sequence, and the immune response regulatory sequence comprises a transcription factor binding regulatory element RE which is co-stimulated and regulated by transcription factors AP-1 and CD28. The invention also provides an in-vitro immune effector function reporter gene cell model containing the nucleic acid construct, and the cell model can realize effector function activity determination performance of sensitive and potent signals so as to evaluate ADCC and ADCP killing action mechanisms and titers mediated by antibody-dependent disease cells designed by an Fc structural domain of a therapeutic antibody product. In addition, the immunosuppression and regulation efficacy of a targeted CTLA-4 or Abatacept mediated treatment method on a CD28 co-activation pathway can be evaluated.

The invention is suitable for the technical field of biology, and provides an L-NAME induced trophoblast organ injury model and a construction method and application thereof, and the construction method of the trophoblast organ injury model comprises the following steps: constructing a trophoblast organ by using human villus tissue; the method comprises the following steps: carrying out culture and passage treatment on a trophoblast organ, and then adding L-NAME with the final concentration of 15-60mM to carry out induced injury, so as to obtain the trophoblast organ injury model. The basic model used in the invention is a trophoblast-like organ which can be subcultured for a long time, so that the problems of difficult acquisition of placenta samples and ethics limitation in the clinical early stage are reduced. Meanwhile, L-NAME is used for performing drug-induced injury, a trophoblast organ injury model for simulating the placental pathological state of preeclampsia can be constructed, and compared with traditional hypoxia-induced injury, the method is more convenient, and the limitation of instruments and equipment is reduced.

The invention provides an organoid culture medium, an organoid culture method and application of the organoid culture medium, the organoid culture medium comprises a first-stage culture medium, the first-stage culture medium comprises a first-stage basic culture medium and first-stage addition factors, and the first-stage addition factors comprise N-acetylcysteine, nicotinamide, a ROCK inhibitor, Noggin, R-spondin, EGF, HGF, Gastrin, FGF10, Blebbistatin, Forskolin, A83-01, LDN193189, DAPT, TGF-alpha and UDAC. By using the organoid culture medium, the liver organoid and the fatty liver organoid can be effectively obtained, and the obtained fatty liver organoid has obvious fat deposition, is sensitive to fatty liver treatment drugs, highly restores the physiological status when human body fatty liver diseases occur, and has high application value.

The invention relates to the technical field of cell biology, and particularly discloses an isolated culture method of primary meibomian gland epithelial cells, the obtained primary meibomian gland epithelial cells and application of the primary meibomian gland epithelial cells. The method comprises the following steps: efficiently and mildly digesting meibomian gland tissues by adopting a compound digestive juice consisting of I-type collagenase, dispersing enzyme and trypsin in a specific ratio; stopping digestion by using a serum-containing neutralizing solution and collecting cells; the method comprises the following steps: promoting cell attachment by using a serum-containing initial culture medium, and carrying out selective amplification by using a serum-free proliferation culture medium to finally obtain high-purity and high-activity primary meibomian gland epithelial cells. The method solves the problems of long digestion time, low cell yield, poor purity and the like in the traditional method. The obtained cell can be used for constructing a meibomian gland dysfunction model, screening drugs and researching lipid metabolism, and an important technical platform and a cell model are provided for research and treatment of related eye diseases.